Oral route of mini-proinsulin-expressing Ganoderma lucidum decreases blood glucose level in streptozocin-induced diabetic rats

International Journal of Molecular Medicine

Volumn 20, Issue 1, 2007, Pages 45-51

  Ni, Ting ^a   Hu, Yuanlei ^a   Sun, Li ^a   Chen, Xi ^a   Zhong, Jin ^a   Ma, Hong ^a   Lin, Zhhongping ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Blood glucose; G. lucidum; Mini proinsulin; Oral route

Indexed keywords

ANTIDIABETIC AGENT; MINIPROINSULIN; PROINSULIN; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CHEMICAL MODEL; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; FUNGAL GENE; GANODERMA LUCIDUM; GENETICS; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PANCREAS; PROTEIN SECONDARY STRUCTURE; RAT; SPRAGUE DAWLEY RAT; TRANSGENIC PLANT;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GENES, FUNGAL; HYPOGLYCEMIC AGENTS; MALE; MODELS, CHEMICAL; PANCREAS; PLANTS, GENETICALLY MODIFIED; PROINSULIN; PROTEIN STRUCTURE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; REISHI;

EID: 34548085767     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.20.1.45     Document Type: Article

References (26)

1. Atkinson MA and Maclaren NK: The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 331: 1428-1436, 1994.
2. Bergenstal RM: Treatment models from the international diabetes center: advancing from oral agents to insulin therapy in type 2 diabetes. Endocr Pract 12 (Suppl 1): 98-104, 2006.
3. + T cells that suppress adoptive transfer of diabetes. J Autoimmun 7: 655-663, 1994.
4. Bergerot I, Fabien N, Mayer A and Thivolet C: Active suppression of diabetes after oral administration of insulin is determined by antigen dosage. Ann NY Acad Sci 778: 362-367, 1996.
5. Jederstrom G, Grasjo Nordin A, Sjoholm I and Andersson A: Blood glucose-lowering activity of a hyaluronan-insulin complex after oral administration to rats with diabetes. Diabetes Technol Ther 7: 948-957, 2005.
6. 2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol Pharm Bull 16: 68-72, 1993.
7. Yamamoto A, Taniguchi T and Rikyuu K: Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res 11: 1496-1500, 1994. (Pubitemid 24339662)
8. Tozaki H, Nishioka J, Komoike J, Okada N, Fujita T, Muranishi S, Kim SI, Terashima H and Yamamoto A: Enhanced absorption of insulin and (Asu(1,7))eel-calcitonin using novel azopolymercoated pellets for colon-specific drμg delivery. J Pharm Sci 90: 89-97, 2001.
9. Carino GP, Jacob JS and Mathiowitz E: Nanosphere based oral insulin delivery. J Controlled Release 65: 261-269, 2000.
10. Wu ZH, Ping QN, Wei Y and Lai JM: Hypoglycemic efficacy of chitosan-coated insulin liposomes after oral administration in mice. Acta Pharmacol Sin 25: 966-972, 2004.
11. Murray EE, Lotzer J and Eberle M: Codon usage in plant genes. Nucleic Acids Res 17: 477-498, 1989.
12. Sun L, Cai HQ, Xu WH, Hu YL, Gao Y and Lin ZP: Efficient transformation of the medicinal mushroom G. lucidum. Plant Mol Biol Reporter 19: 383a-383j, 2001.
13. Wandelt CI, Khan MR, Craig S, Schroeder HE, Spencer D and Higgins TJ: Vicilin with carboxy-terminal KDEL is retained in the endoplasmic reticulum and accumulates to high levels in the leaves of transgenic plants. Plant J 2: 181-192, 1992.
14. Arakawa T, Yu J, Chong DK, Hough J, Engen PC and Langridge WH: A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 16: 934-938, 1998.
15. Gong Z, Jin Y and Zhang Y: Oral administration of a cholera toxin B subunit-insulin fusion protein produced in silkworm protects against autoimmune diabetes. J Biotechnol 119: 93-105, 2005.
16. Hu H, Ahn NS, Yang X, Lee YS and Kang KS: G. lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer 102: 250-253, 2002.
17. Kino K, Yamashita A, Yamaoka K, Watanabe J, Tanaka S, Ko K, Shimizu K and Tsunoo H: Isolation and characterization of a new immunomodulatory protein, ling zhi-8 (LZ-8), from Ganoderma lucidium. J Biol Chem 264: 472-478, 1989.
18. Kino K, Mizumoto K, Sone T, Yamaji T, Watanabe J, Yamashita A, Yamaoka K, Shimizu K, Ko K and Tsunoo H: An immunomodulating protein, Ling Zhi-8 (LZ-8) prevents insulitis in non-obese diabetic mice. Diabetologia 33: 713-718, 1990.
19. Kim S, Song J and Choi HT: Genetic transformation and mutant isolation in G. lucidum by restriction enzyme-mediated integration. FEMS Microbiol Lett 233: 201-204, 2004.
20. Gao XX, Yang Q, Song JZ and Guo ZK: Agrobacterium tumefaciens-mediated transformation of trichoderma harzianum. High Tech Lett 15: 32-35, 2004.
21. Shin CS, Hong MS, Bae CS and Lee J: Enhanced production of human mini-proinsulin in fed-batch cultures at high cell density of Escherichia coli BL21(DE3)(pET-3aT2M2). Biotechnol Prog 13: 249-257, 1997.
22. Thim L, Hansen MT and Sorensen AR: Secretion of human insulin by a transformed yeast cell. FEBS Lett 212: 307-312, 1987.
23. Chang SG, Kim DY, Choi KD, Shin JM and Shin HC: Human insulin production from a novel mini-proinsulin which has high receptor-binding activity. Biochem J 329: 631-635, 1998.
24. Pais-Chanfrau JM, Garcia Y, Licor L, Besada V, Castellanos-Serra L, Cabello CI, Hernandez L, Mansur M, Plana L, Hidalgo A, et al: Improving the expression of mini-proinsulin in Pichia pastoris. Biotechnol Lett 26: 1269-1272, 2004.
25. Perczel A, Jakli I and Csizmadia IG: Intrinsically stable secondary structure elements of proteins: a comprehensive study of folding units of proteins by computation and by analysis of data determined by X-ray crystallography. Chemistry 9: 5332-5342, 2003.
26. Yang AS, Hitz B and Honig B: Free energy determinants of secondary structure formation: III. beta-turns and their role in protein folding. J Mol Biol 259: 873-882, 1996.